申请人:Merrell Toraude et Compagnie
公开号:US04421767A1
公开(公告)日:1983-12-20
Compounds of the formula: ##STR1## wherein: X is fluorine, chlorine, or bromine; R is the group R.sub.2 as defined below; R.sub.1 is a group of the formula: ##STR2## or the group R.sub.2 as defined below; wherein R.sub.2 is: ##STR3## wherein R.sub.3 is hydrogen, (C.sub.1 -C.sub.4)alkyl, or (C.sub.1 -C.sub.4)alkoxy, and R.sub.4 is (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy; or a (C.sub.1 -C.sub.8)alkyl ester thereof; or a non-toxic pharmaceutically acceptable salt thereof, inhibit MAO in vivo and can be administered either alone or in combination with an aromatic L-amino acid decarboxylase inhibitor for the treatment of depression.
该化合物的公式为:其中:X为氟、氯或溴;R为下文所定义的R.sub.2基团;R.sub.1为下列公式的基团:或下文所定义的R.sub.2基团;其中R.sub.2为:其中R.sub.3为氢、(C.sub.1 -C.sub.4)烷基或(C.sub.1 -C.sub.4)烷氧基,R.sub.4为(C.sub.1 -C.sub.4)烷基或(C.sub.1 -C.sub.4)烷氧基;或其(C.sub.1 -C.sub.8)烷基酯;或其无毒的药用可接受盐,能够在体内抑制MAO,并可单独或与芳香族L-氨基酸脱羧酶抑制剂联合使用,用于治疗抑郁症。